AN INEFFECTIVE LINEAR PIPELINE

Only 5% of drugs showing preclinical efficacy progress beyond Phase III oncology trials

The current oncology drug development process is fundamentally flawed. It adheres to a linear methodology that predominantly depends on cancer cell lines and animal models. These traditional models, however, fail to replicate the intricate and heterogeneous nature of human tumors, resulting in late-stage failures and substantial financial losses.

A PATIENT IN THE LAB

HUB Organoids bridge the translational gap and shorten the
time from drug discovery to clinical trials in just 5 years

  • Derived from
    adult stem cells
  • Physiologically and
    biologically relevant
  • High establishment efficiency
  • Genetically and
    phenotypically stable
  • Preserve patient and
    disease specific antigens
  • Amenable to co-cultures with immune, stromal cells or bacteria
  • Can be developed from virtually any preclinical species
  • Expandable for large-scale screens
  • Suitable for genetic manipulation
  • Account for on-target and off-target toxicities
A PATIENT-CENTRIC APPROACH

HUB Organoids value chain spans across the continuum of oncology drug development

 

OUR SERVICES

PDO Screen

Fast and cost-effective screening on a preset panel of tumor organoids

PDO Screen is built upon the recent success of our organoid screening platform which led to the first oncology agent to be approved for clinical trials within 5 years of development. Select from a pre-set panel of patient-derived organoid models among the available tissue types for a fast, cost-efficient, and patient-relevant evaluation of your agent efficacy.

enrol now

PDO Co-cultures

Organoid-based immune cell co-culture platform

The development of successful oncology agents requires evaluating a drug’s impact on the epithelium as well as the immune and stromal cells. Modeling these intricate interactions in vivo often compromises scalability and cost, posing a hurdle in preclinical drug development. We offer unique organoid co-culture systems with various immune cells like autologous and allogeneic T cells, macrophages, neutrophils, NK cells, and fibroblasts. This allows for a deeper understanding of drug responses and paves the way for the development of next-generation cancer immunotherapies.

talk to an expert

Explore the science behind

CASE STUDY

Drug discovery to clinical trials in five years

download now

FACTSHEET

Tumor organoids for cancer research

download now

WHITE PAPER

Accelerating oncology drug discovery with HUB Organoids

view publication

Book your screen

Share your screening parameters with us. Our experts will get in touch with you shortly.
X

Have any questions?

contact us